MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME: GUIDELINES FOR MANAGEMENT IN LJUBLJANA REGION

  • Igor Kranjec Klinični oddelek za kardiologijo Interna klinika Klinični center Zaloška 7 1525 Ljubljana
  • Marko Noč Center za intenzivno interno medicino Interna klinika Klinični center Zaloška 7 1525 Ljubljana

Abstract

*

Downloads

Download data is not yet available.

References

Davies M. Acute coronary thrombosis: the role of plaque disruption and its initiation and prevention. Eur Heart J 1995; 16: Suppl L: 3–7.

McCarthy B, Wong J, Selker H. Detecting acute ischemia in the emergency department. J Gen Int Med 1990; 5: 365–73.

WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Circulation 1994; 90: 583–612.

The Pursuit trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–43.

Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O’Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, Califf RM, Topol EJ. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996; 335: 1333–41.

European Society of Cardiology. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406–32.

ACC/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee on the management of patients with unstable angina). Circulation 2000; 102: 1193–209.

European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 1996; 17: 43–63.

ACC/AHA. 1999 Update: ACC/AHA Guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on management of acute myocardial infarction). Circulation 1999; 100: 1016–30.

European Society of Cardiology. Myocardial infarction redefined – a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. The Joint European Society of Cardiology/American College of Cardiology Committee. Eur Heart J 2000; 21: 1502–13.

Brener SJ, Bar LA, Burchenal JEB, Katz S et al. on behalf of the ReoPro and Primary PTCA organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734–41.

O’Shea C, Tcheng JE. Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction. J Invas Cardiol 1999; 11: 494–9.

van den Merkhof LF, Zijlstra F, Olsson H, Grip L et al. Abciximab in the treatment of acute MI eligible for primary percutaneous transluminal coronary angioplasty. Results of the GP Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 1999; 33: 1528–32.

Topol EJ, Moliterno DJ, Hermann HC, Powers ER et al. for the TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888–94.

The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–61.

The Fibrinolytic Therapy Trialists. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–22.

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. B Med J 1994; 308: 81–95.

CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 1996; 348: 1329– 39.

ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 2: 57–66.

Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto miocardico. GISSI-3: Effects of lisinopril and transdermal nitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22.

ISIS-4 Collaborative Group. A randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium in 58,000 patients with suspected acute myocardial infarction. Lancet 1994; 345: 669–85.

Hamm CW, Ravkilde J, Gerhardt W. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146–50.

The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in addition to Aspirin in Pts with acute coronary syndromes without ST-segment elevation. N Engl J Med 345; 494– 502.

The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429–35.

The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–53.

The PARAGON investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a Global Organization Network. Circulation 1998; 97: 2386–95.

The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488–97.

The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in pts with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915–24.

Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave MI. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602–8.

Fragmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701–7.

FRAXIS study group. Comparison of two treatment durations of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction. Eur Heart J 1999; 20: 1553–62.

TIMI-IIIb Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-ST elevation myocardial infarction: results of the TIMI IIIb trial. Circulation 1994; 89: 1545–56.

Boden WE, O’Rourke RA, Crawford MH. Outcomes in patients with acute non-Q wave myocardial infarction randomly assigned to an invasive as compared to a conservative management strategy. N Engl J Med 1998; 338: 1785–92.

Cannon CP, Weintraub WS, Demopoulos, Vicari R et al. for the TACTICSThrombolysis In MI 18 Investigators. Comparison of early invasive and conservative strategies in pts with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–87.

The EPISTENT Investigators. Randomised placebo-controlled and balloonangioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87–92.

How to Cite
1.
Kranjec I, Noč M. MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME: GUIDELINES FOR MANAGEMENT IN LJUBLJANA REGION. TEST ZdravVestn [Internet]. 1 [cited 5Aug.2024];71(7/8). Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/1616
Section
Quality and safety

Most read articles by the same author(s)